Review Article

Steroids in pediatric acute respiratory distress syndrome

Nicolás Monteverde-Fernández¹,², Federico Cristiani³, Jenniffer McArthur⁴, Sebastián González-Dambrauskas¹,⁵

¹Red Colaborativa Pediátrica de Latinoamérica (LARed Network), Uruguay; ²Medica Uruguaya Corporación Asistencia Médica (MUCAM). Cuidados Intensivos Neonatales y Pediátricos (CINP), Uruguay; ³Department of Anesthesiology, Centro Hospitalario Pereira Rossell, Cátedra de Anestesiología, Universidad de la República, Montevideo, Uruguay; ⁴Division of Critical Care, Department of Pediatrics, St. Jude's Children’s Research Hospital, Memphis, TN, USA; ⁵Cuidados Intensivos Pediátricos Especializados (CIPe) Casa de Galicia, Montevideo, Uruguay

Keywords: Acute lung injury, acute respiratory distress syndrome (ARDS); Pediatric acute respiratory distress syndrome (PARDS); pulmonary therapies; steroids

Abstract: Acute respiratory distress syndrome (ARDS) is a complex entity with high potential for harm and healthcare resource utilization. Despite multiple clinical advances in its ventilatory management, ARDS continues to be one of the most challenging disease processes for intensivists. It continues to lack a direct, proven and desperately needed effective therapeutic intervention. Given their biologic rationale, corticosteroids have been widely used by clinicians and considered useful by many in the management of ARDS since its first description. Adult data is abundant, yet contradictory. Controversy remains regarding the routine use of corticosteroids in ARDS. Therefore, widespread evidence-based recommendations for this heterogeneous disease process have not been made. In this article, our aim was to provide a summary of available evidence for the role of steroids in the treatment of ARDS, while giving special focus on pediatric ARDS (PARDS).

Introduction

Acute respiratory distress syndrome (ARDS) research has recently celebrated its 50th birthday (1). Despite clinical advances, ARDS continues to be one of the most challenging disease processes that intensivists face in their clinical practice, causing high mortality and disabling consequences in survivors (2). Although pathophysiological similarities exist at all ages, in the last few years the pediatric critical care community has recognized that children beyond the neonatal period have their own distinctive features and deserve special focus (3-5). Children cannot be treated as little adults and ARDS in children is now known as a specific identity: pediatric ARDS (PARDS).

In 2015, the first pediatric-specific ARDS definition was developed during the Pediatric Acute Lung Injury Consensus Conference (PALICC) with an intent to address the specific characteristics of PARDS and promote a better understanding of the syndrome (6).

From a general public health standpoint, PARDS would be considered rare. One study from the US revealed an annual incidence of 12.8 cases per 100,000 (7). Another from Australia and New Zealand found an incidence of 2.95/100,000 persons <16 years (8). Though PARDS is not as prevalent as diseases such as cancer or asthma, its high potential for harm and high resource utilization make it worthy of further study.

Thousands of children die every year in pediatric intensive care units (PICUs) from PARDS. Using PALICC diagnostic criteria, studies have shown that
PARDS is a common reason for PICU admission (9-11). It carries high mortality in children admitted to PICUs worldwide. In a general PICU population in urban India, PARDS had a prevalence of 9.9% and mortality up to 51.4% (9). Some pediatric populations such as hematopoietic stem cell transplant recipients are at even higher risk of both, developing PARDS (91.5% meet PARDS criteria within first week of intubation) and dying from it (60.6% mortality) (10). To date, the largest available epidemiological study comes from the PARDS incidence and epidemiology (PARDIE) study (11). Data was gathered from 135 PICUs in 27 countries. PARDIE found that PARDS affected 3% of patients treated in PICUs and a 17% overall mortality. The mortality rate was over 30% in the most severe hypoxemic forms. It is clear than effective interventions are desperately needed for PARDS.

Management for established PARDS remains supportive, with timely identification and treatment of the underlying cause. Despite being an important disease process in the critical care field, no specific pharmacological treatment has proven to be effective in improving significant clinical outcomes. In 2015, PALICC reviewed the available pulmonary specific ancillary treatments for PARDS and concluded that pharmacological therapies commonly used in clinical practice had low quantity of scientific evidence and their routine use could not be recommended (12).

Steroids have been proposed as beneficial and widely used since ARDS first formal description by Ashbaugh et al. (13). In their landmark study, they reported steroids use in 9 of 12 patients, highlighting dramatic response in one of them, good response in another and no clinical benefit in the rest. They stated in their discussion “the value of corticosteroids probably lies in their anti-inflammatory antiedema effect”.

Fifty years after this landmark Lancet study describing steroid use in ARDS, controversy remains regarding their benefit in this complex and severe inflammatory disease. The purpose of this review is to compare, and contrast published research on the use of steroids in ARDS, with special focus on PARDS. We conducted a literature search considering articles in English or Spanish from earliest available date until December 2018 using the following sources: PubMed/Medline, Google scholar, Pictrials.net and clinicaltrials.gov. We identified studies using combined terms and synonyms for steroids and ARDS and included Medical Subject Headings (MeSH) when available. Relevant additional publications were also screened manually for publications from the articles identified in the original review of databases. For analysis in this review, we prioritized prospective, randomized controlled articles (RCTs), meta-analyses and observational studies articles. Manuscripts were segregated into adult and pediatric with various categories namely pathophysiology, pharmacological properties, epidemiology, outcomes. The authors divided categories to review. A final review process was taken by all authors.

**Biological/pharmacological rationale of use of steroids in PARDS**

PARDS is defined as a noncardiogenic pulmonary edema characterized by an intense pulmonary inflammatory reaction, acutely developing in 12 to 48 hours in the context of a severe systemic illness resulting in hypoxemic respiratory failure (14). It is caused primarily by damage to the alveolar epithelial endothelial permeability barrier. The disruption in permeability of this membrane results in accumulation of fluid in the alveoli. Increased permeability of the alveolar capillary membrane results in protein rich neutrophilic exudate, interstitial and alveolar edema, and hyaline membranes. These pathologic abnormalities, lead to worsened gas exchange and reduced pulmonary compliance. This pathophysiology in the lung occurs in the setting of dysregulated inflammation, inappropriate activity of leukocytes and platelets, and uncontrolled activation of coagulation pathways (15,16).

While a regulated inflammatory response is critical to survival, a major predictor of poor outcome in ARDS patients is persistence of pulmonary and systemic inflammation after one week of lung injury. The inability to down regulate inflammatory mediator production leads to inappropriate alveolar-capillary membrane repair and impaired pulmonary gas exchange and compliance (17,18). Cytokines released in PARDS stimulate the synthesis and action of cortisol by direct action on the hypothalamic-pituitary-adrenal (HPA) axis and glucocorticoid receptor (GR). Studies suggest that PARDS may be associated with critical illness-related corticosteroid insufficiency. This is defined as inadequate corticosteroid activity for the severity of a patient’s illness and occurs as a result of a decrease in adrenal steroid production due to dysfunction at any point in the hypothalamic-pituitary-adrenal axis or due to tissue resistance to glucocorticoids (19,20).

Two cellular signaling pathways are central to the regulation of inflammation: the stimulatory nuclear factor (NF)-kB and the inhibitory GR mediated signal transduction.
Steroids are potentially useful in PARDS. However, based on evidence, they are predominantly sequestered in the cytoplasm. The activation of NF-kB is the essential step in the experimental development of neutrophilic lung inflammation. NF-kB, bound to inhibitory proteins in the cytoplasm (I-kB), is activated by several stimuli, such as lipopolysaccharide, physical or chemical stress, and inflammatory cytokines. This activation induces translocation of NF-kB into the nucleus where it binds to the promoter regions of target genes and initiates the transcription of multiple cytokines such as tumor necrosis factor (TNF), interleukin (IL)-1, IL-6, intracellular adhesion molecule (ICAM) 1, selectin E, and other inflammatory mediators (17,21). After entering the cell, corticosteroids bind to GR in the cytoplasm, with the activation of glucocorticoid-receptor (GC-GR) complex. The GC-GR complex then moves into the nucleus and promotes activation or repression of the transcription of associated genes. The GC-GR complex may also indirectly affect cell function by binding to and modulating transcription factors such as NF-kB. Corticosteroids may inhibit NF-kB activity either by directly binding to it or increasing I-kB proteins transcription (21,22).

In this way, steroids counteract almost every step of the inflammatory cascade, modulating the immune response. They cause a decrease in the production of cytokines and facilitate the production of macrophage migration inhibitory factor. Additional effects of steroids contribute to the maintenance of homeostasis during severe illness. Metabolic effects, especially stimulation of gluconeogenesis and glycogenolysis, increase the availability of energetic substrates. Cardiovascular effects maintain vascular tone, potentiate the vasoconstrictor action of catecholamines and decreases the production of nitric oxide. This favors the distribution of fluids within the vascular compartment (23).

There are several conditions for which steroids effects may be beneficial in patients with PARDS: treatment of a coexistent steroid-responsive disease; treatment of inflammation early in the course of ARDS to minimize lung damage; treatment of maladaptive healing responses late in the course of ARDS to improve lung function; treating the critical illness-related corticosteroid insufficiency; and treating the inflammatory effects of mechanical ventilation (20,21,24,25).

Steroids are potentially useful in PARDS. However, because of their broad mechanism of action effecting multiple systems, patients may develop multiple adverse effects. The first publications that express concern about the safety of steroids were in mid-20th century, when there has been an expansion in the use of corticosteroids in pediatrics (26,27). The main concerns were gastrointestinal bleeding; immunosuppression leading to worsening of an existing infection; metabolic effects such as hyperglycemia, retention of sodium chloride and water and loss of potassium; hypertension; psychiatric effects such as insomnia, psychosis and delirium; and decrease in growth with prolonged use. These effects may be of clinical significance in critically ill patients with PARDS (26,28-31).

Steroid use has also been implicated in acquired neuromyopathy. These drugs cause direct myotoxicity. Intensive care unit (ICU) acquired neuromuscular weakness involves dysfunction of the nerves, muscles, or both. Nerves may be functionally impaired or completely denervated and skeletal muscles can have both impaired contractility and diminished mass from a combination of decreased protein synthesis and increased proteolysis (32,33). Although steroid therapy may be involved in the development of ICU-acquired neuromyopathy, there are other contributing factors such as systemic inflammation (increased inflammatory cytokine levels), organ dysfunction, use of neuromuscular blockade and general immobility while ventilated (34). Studies have failed to demonstrate steroid causality in neuromuscular weakness, as it is difficult to control all other risk factors (25).

Evidence in support of corticosteroids for PARDS

While evidence is lacking to recommend widespread use of corticosteroids in PARDS, there are hints at their utility in ill-defined subgroups of PARDS. ARDS is characterized by inflammation (18). Therefore, the use of medications known to control inflammation have been of interest for decades.

Animal data and translational studies support the rationale for the use of steroids in PARDS. Methylprednisolone given prior to collapsing one lung in a piglet model of single lung ventilation reduced inflammatory mediators in the collapsed as well as the ventilated lung (35). In a rat model of endotoxin induced ARDS given ventilator induced lung injury, rats treated with inhaled budesonide had lower levels on inflammatory cytokines in bronchial alveolar lavage fluid (BALF) compared with rats given saline. However, budesonide treated rats had higher levels of the anti-inflammatory cytokine, IL-10, in BALF. Budesonide treated rats also had less histopathological changes of ARDS and improved survival compared with rats given saline (36).
l lung injury, mice given concomitant methylprednisolone had less markers of lung inflammation as evidenced by less pathophysiological changes in lung histology, less inflammatory mediators found in BALF and better markers of lung compliance. Methylprednisolone treated mice had an increased M2/M1 macrophage ratio which in turn induced more T-regulatory cells, a cell type important for its anti-inflammatory effect (37). Therefore, animal data would suggest that corticosteroids may play a role in ameliorating inflammation in ARDS which in turn would lead to improved clinical outcomes.

Adult data regarding the use of corticosteroids in ARDS has been somewhat confusing with some studies showing benefit while others did not (38,39). The most positive results came from studies by Meduri et al. One of their first studies was a randomized placebo-controlled trial of adults with ARDS that had not improved by day 7 of mechanical ventilation. Subjects randomized to the treatment arm received 2 mg/kg methylprednisolone for 14 days which was then weaned slowly through day 32 (40). By study day 10, patients in the treatment arm had reduced lung injury scores (1.7 in treatment arm vs. 3.0 in placebo, P<0.001), improved partial pressure of arterial oxygen to inspired fraction of oxygen (PaO_2/FiO_2) ratio (262 in treatment group vs. 148 in placebo arm, P<0.001), and better rates of successful extubation (7/16 patients in treatment arm vs. 0/8 in placebo arm, P=0.05). Overall mortality was lower in the treatment arm as well [0/16 (0%) in treatment arm vs. 5/8 (62%) in placebo arm, P=0.002]. An ancillary study to this trial compared cytokines and glucocorticoid levels in the two groups (41). Patients who received methylprednisolone had decreased inflammatory cytokine levels compared to the control group. Peripheral blood leukocytes donated from healthy volunteers and exposed to the serum from the methylprednisolone group had progressive increases in GR activity prompting investigators to conclude that inflammation-induced glucocorticoid resistance played a role in the prolonged inflammatory response seen in patients with prolonged ARDS. The authors felt the beneficial effect of methylprednisolone in unresolving ARDS was not so much from excessive anti-inflammatory effect but was more so due to restoration of homeostasis in a system that was out of control from glucocorticoid resistance. A subsequent larger study by Meduri et al. randomized patients earlier in their course of ARDS and used a slightly different dosing regimen (42). Ninety-one adult patients with severe early ARDS (≤72 hours) were randomized to treatment with a methylprednisolone infusion of 1 mg/kg/day for up to 28 days vs. placebo. Those in the treatment arm had decreased length of mechanical ventilation [median, 5 days (range, 3–8 days) in treatment arm vs. 9.5 days (range, 6–19.5 days) in placebo arm, P=0.002], decreased ICU length of stay [median 7 days (range, 6–12 days) in treatment arm vs. 14.5 days (range, 7–20.5 days) in placebo arm, P=0.007], decreased ICU mortality [13/63 patients in treatment arm vs. 12/28 patients in placebo arm, relative risk (RR) 1.39; 95% confidence interval (CI), 0.98–1.96, P=0.03] and a lower rate of infection (40 new infections in 63 patients in treatment arm vs. 40 new infections in 28 patients in placebo arm, P=0.0002).

A subsequent ARDSnet trial randomized 180 adults with ARDS to methylprednisolone vs. placebo (43). Patients enrolled between day 7 to day 28 of ARDS. Patients randomized to the treatment arm received methylprednisolone 2 mg/kg/day for 14 days followed by 1 mg/kg/day for 7 days, then were slowly tapered off over the next several days. If patients exubated prior to the first 3 weeks, once they had tolerated extubation for 48 hours, they were rapidly weaned from corticosteroids over 48 hours. There was no difference in the primary outcome of the trial, 60-day mortality, leading the authors to conclude there was no role for steroids in ARDS. However, in closer examination of their secondary outcomes, there is data supporting the use of corticosteroids. Patients in the methylprednisolone group had a faster time to extubation (14.1 days in treatment arm vs. 23.6 days in placebo arm, P=0.006), increased mean ventilator free days at day 28 (6.8±8.5 days in treatment arm vs. 11.2±9.4 days in placebo arm, P<0.001), increased mean cardiovascular failure free days (17.9±10.2 days in treatment arm vs. 20.7±8.9 in placebo arm, P=0.03) and improved markers of lung compliance without an increased risk of infection.

Two meta-analyses were performed shortly after the previously discussed studies were completed. These showed mixed results with one showing no conclusive evidence for the use of corticosteroids in ARDS (38) while the other showed benefit in the same population (39). Meta-analyses of steroid trials in adults with ARDS published in this decade have universally shown improved outcomes in the corticosteroid group (44,45). Meduri et al. analyzed individual patient data from 4 randomized controlled trials (RCTs) of corticosteroids in adults with ARDS (45). The individual patient data was added to available aggregate data from 4 additional trials of hydrocortisone in early ARDS. This meta-analysis showed improved hospital mortality, increase in ventilator...
were associated with a higher severity of α

Table 1

© Annals of Translational Medicine. All rights reserved.

ann Transl Med

were associated with a higher severity of α

Table 1

© Annals of Translational Medicine. All rights reserved.

were associated with a higher severity of α

Table 1

© Annals of Translational Medicine. All rights reserved.

were associated with a higher severity of α

Table 1

© Annals of Translational Medicine. All rights reserved.

were associated with a higher severity of α

Table 1

© Annals of Translational Medicine. All rights reserved.

were associated with a higher severity of α

Table 1

© Annals of Translational Medicine. All rights reserved.

were associated with a higher severity of α

Table 1

© Annals of Translational Medicine. All rights reserved.

were associated with a higher severity of α

Table 1

© Annals of Translational Medicine. All rights reserved.
Monteverde-Fernández et al. Steroids in PARDS

60-day mortality. In the cohort studies which included 749 patients, corticosteroids had no effect on ICU mortality and a non-significant increase on 60-day mortality. When subgroups were analyzed, the results revealed that the response to steroids varied according with the etiology of ARDS and the timing of initiation of steroids. When the etiology of ARDS was considered, patients with influenza related ARDS had a higher mortality with steroid use (63). This data is particularly concerning for children since H1N1 influenza virus is known to cause particularly severe PARDS (64,65).

Steinberg et al. found in the 2006 ARDSNet study that enrollment after day 13 of ARDS diagnosis was associated with a significantly higher mortality rate (43). The

| Table 1 Summary of most relevant guidelines and clinical studies of steroids in the management of ARDS (both adult and/or pediatric populations) |
|---|---|---|---|
| Reference | Population | Study type | Recommendation/findings |
| FICM/ICS (53), 2018 | Adult | Guidelines | Corticosteroids in established ARDS needs further study |
| Annane et al. (54), 2018 | Adult | Guidelines | Corticosteroids beneficial in early moderate to severe ARDS (PaO₂ /FiO₂ of <200 and within 14 days of onset) |
| Hashimoto et al. (55), 2017 | Adult | Guidelines | Methylprednisolone equivalents 1–2 mg/kg/day recommended for adults with ARDS in ICU |
| Festic et al. (56), 2017 | Adult | RCT | Placebo group with higher rate of ARDS and need for mechanical ventilation |
| Meduri et al. (45), 2016 | Adult | Meta-analysis | Improved ICU length of stay and ventilator free days in steroid groups; improved hospital survival with early initiation (<14 days) of steroids |
| Tongyoo et al. (57), 2016 | Adult | RCT | Hydrocortisone associated with improved lung injury score but no survival benefit |
| Cho et al. (58), 2016 | Adult | Guidelines | Low dose systemic steroids in early ARDS may improve hypoxemia and reduce the length of MV, ICU LOS & mortality. Low dose systemic steroids in early ARDS may improve hypoxemia and reduce the length of MV, ICU LOS & mortality |
| Tamburro et al. (12), 2015 | Children | Guidelines | Corticosteroids not recommended routinely |
| Drago et al. (51), 2015 | Children | RCT | Study feasible; no detectable adverse events |
| Zhang et al. (59), 2015 | Adult | Secondary analysis of RCT | Non-survivors more likely to have received steroids > methylprednisolone 20 mg equivalent dose |
| Yehya et al. (60), 2015 | Children | Prospective observational | 60% ventilated children meeting PALICC criteria received corticosteroids more than 24 h |
| Santschi et al. (61), 2013 | Children | Survey | 30–35% pediatric intensivists would use steroids in worsening PARDS |
| Santschi et al. (52), 2010 | Children | Prospective observational | 35% children with ALI received steroids |
| Meduri et al. (42), 2007 | Adult | RCT | Methylprednisolone group with improved lung injury score, ICU length of stay, duration of mechanical ventilation and ICU mortality |
| Steinberg et al. (43), 2006 | Adult | RCT | Methylprednisolone group with improved shock free days and ventilator free days at day 28 |
| Annane et al. (62), 2006 | Adult | Retrospective | In patients with septic shock- associated ARDS, Non-responders (shock not reversed by study drug) who received steroids (vs. placebo) had improved survival and less time on MV |

ALI, acute lung injury; ARDS, acute respiratory distress syndrome; ICU, Intensive care unit; LOS, length of stay; MV, mechanical ventilation; PARDS, pediatric acute respiratory distress syndrome; RCTs, randomized controlled trials.
ARDSNet findings suggest that if there is any benefit to be gained from the use of steroids in persistent ARDS, that they should be started before day 14. Zhang et al. performed a post-hoc analysis of a rosuvastatin trial in adults with ARDS (59). They compared steroid usage in 540 survivors vs. 205 non-survivors and found that use of steroids at a minimum dose of 20 mg methylprednisolone equivalents was not associated with an effect on mortality after adjusting for confounding factors [odds ratio (OR) 1.18; 95% CI, 0.81–1.71].

Tongyoo et al. conducted a single-center double-blind randomized, placebo-controlled trial, in 197 adult patients with sepsis-associated ARDS (57). Patients were randomized to hydrocortisone 50 mg every 6 hours for 7 days or placebo. Hydrocortisone was associated with a significant improvement in pulmonary physiology as measured by PaO/FiO and lung injury scores, but did not show a significant survival benefit or difference in length of mechanical ventilation.

The Meduri group has criticized these negative results. They asserted that current reviews and meta-analyses should be limited to trials where low to moderate daily doses have been investigated such as methylprednisolone ≤1 mg/kg/day in early phase ARDS, or ≤2 mg/kg/day for late phase ARDS (45). They argued that the negative meta-analyses include early studies using very high doses of methylprednisolone or rapid tapering of steroids, both practices that are now known to lack benefit and potentially cause harm (66). Criticism for Meduri’s meta-analysis is based upon potential academic bias given that he is the author of nearly half of the studies included in his meta-analysis (67).

Recent trials in children failed to show a survival benefit for corticosteroids in ARDS. Drago et al. completed the first RCT of corticosteroids in children with PARDS (51). Thirty-five PARDS patients were randomized to receive placebo versus methylprednisolone 2 mg/kg bolus followed by a continuous infusion of 1 mg/kg/day for 7 days then a slow taper over the subsequent 7 days. Patients in the steroid group had improved PaO/FiO at day 8 and less need for oxygen at ICU transfer. However, there was no significant difference in length of ICU stay, length of hospital stay, ventilator free days or hospital mortality. The authors of this study pointed out that it was not powered to show a survival benefit and that larger studies are both feasible and necessary.

As future studies are developed to definitively answer the steroid debate in PARDS, it will be necessary to tease out the role that an individual’s genetics and the underlying etiology of PARDS play in predicting their response to corticosteroid therapy. As pediatricians we can likely learn much from the studies that have already been completed in adults.

What do guidelines suggest and what should clinicians do?

As described previously, the 2015 PALICC guidelines do not recommend corticosteroids as routine therapy in PARDS (12). Their recommendation against steroid use in PARDS was unambiguous and met the “strong agreement” standard. The authors highlighted the need for future research to identify populations most likely to benefit from steroids as well as optimal dosing regimens.

In 2017, the European Paediatric Mechanical Ventilation Consensus Conference (PEMVECC), stated there were no specific recommendations on corticosteroids use in PARDS other than use in post-extubation stridor prevention (68).

Adult guidelines are contradictory and highlighted the lack of quality evidence (Table 1). Two ARDS guidelines from Asia (55,58) recommend the administration of steroids for adult patients with ARDS (equivalent dose methylprednisolone 1–2 mg/kg/day). The recommendation is based upon the perceived beneficial effect of low dose steroids in early ARDS leading to lessened hypoxemia and decreased duration of mechanical ventilation, not for a reduction in mortality. The 2016 Scandinavian clinical practice guidelines recommend against the routine use of corticosteroids in any dose or duration in adults with ARDS (strong recommendation, low-quality of evidence) (69).

Recently, a task force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM) published recommendations for the management of critical illness-related corticosteroid insufficiency (54). They reviewed 9 trials of prolonged administration of corticosteroids in adults with ARDS. In their review they consistently found the steroid group had decreased markers of inflammation, decreased duration of mechanical ventilation and decreased hospital mortality by 7% in mild ARDS and 11% in severe ARDS. The only risk found in the glucocorticoid group was for hyperglycemia in the first 36 hours after starting steroids. There was no increased risk of neuromuscular weakness, gastrointestinal bleeding or nosocomial infection in the steroid group compared with placebo. Patients who developed hyperglycemia did not have any increased risk of morbidity.
Therefore, the task force recommended methylprednisolone at a dose of 1 mg/kg/day in adults with ARDS and a \( \text{PaO}_2/\text{FiO}_2 \) < 200 within the first 6 days of illness. After day 6 of illness, they recommend increasing the dose to 2 mg/kg/day. They further recommend a slow taper over at least 13 days.

The 2018 Faculty of Intensive Care Medicine (FICM)/Intensive Care Society (ICS) Guidelines for corticosteroids use in adult ARDS were limited to research. The group recommended that corticosteroid use in established ARDS should undergo evaluation in a multicenter RCT (53).

What is recommended in guidelines is not necessarily what clinicians do. In a 2010 cross-sectional study across 59 PICUs from North America and Europe, Santschi et al. reported 35% of PARDS children received corticosteroids (52). Similar numbers emerged in a 2013 international survey of 54 PICU practitioners (47 PICUs in 11 countries). Survey respondents were asked their PARDS management in three different clinical scenarios of acute lung injury (61). Thirty percent responded that they would use steroids in PARDS.

The most detailed description of steroids use in PARDS was the prospective observational single-center study by Yehya et al. (60). In their comprehensive analysis, 60% of ventilated children meeting PALICC criteria received corticosteroids for more than 24 h. A variety of steroid regimens were reported: 51% hydrocortisone, 41% methylprednisolone, 5% dexamethasone, 3% a combination.

In our region Latin-American, there is no published data regarding current practices. We searched the LARed Network registry from May 2017 to December 2018. LARed contains data from 35 PICUs in 8 Latin-Americans countries. During the chosen time period, 3,397 children were admitted with acute respiratory failure, 319 (9.4%) met PARDS criteria and 144 (45.1%) received systemic corticosteroids.

**Conclusions**

Corticosteroid use in PARDS remains an important clinical question. There is a paucity of data in children to guide their use. Data from adult studies have mixed results with some studies showing clear benefit while others do not. This may be explained by radical differences in dosing regimens, patient selection and outcomes measured between trials. Due to the heterogeneous nature of PARDS, it is predictable that steroids do not achieve a homogenous therapeutic response, thus, making universal recommendations nearly impossible.

The most promising results have been in trials utilizing low to moderate doses (equivalent to methylprednisolone 1–2 mg/kg/day), begun relatively early (<3 d in the course of early ARDS, or <14 d in the late ARDS) in the course of ARDS and tapered slowly over time (12 or more days). While there is not adequate evidence to recommend routine use of corticosteroids in PARDS, it is a therapy that desperately warrants further study to identify the correct patient population, timing of administration and dosing regimen.

**Acknowledgments**

None.

**Footnote**

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**References**


33. Hough CL, Steinberg KP, Taylor Thompson B, et al. Intensive care unit-acquired neuromyopathy and...


